Rutgers Cancer Institute | Strategic Alliance Partners

As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.

Connect with us:

Latest from Rutgers Cancer Institute

Advanced Squamous Carcinoma of the Skin: A Persistent, Growing Challenge

September 12, 2015

Article

Advanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.

ORIEN Adds Three Leading Oncology Institutions to Growing Precision Cancer Research Collaboration

July 09, 2015

Article

ORIEN partnership founded by The Ohio State University Comprehensive Cancer Center and Moffitt Cancer Center adds three new members, widens patient access to precision clinical trials.

Immunotherapy in Melanoma: What Does the Future Hold?

June 25, 2015

Article

Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.

Pivotal T-VEC Data Published Ahead of FDA Approval Decision

May 27, 2015

Article

At a recent FDA joint advisory committee meeting, members voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec as a treatment for patients with advanced melanoma.

Clinical Development of Prostate Cancer Vaccines Continues

May 06, 2015

Article

The field of prostate cancer vaccines remains an area of active exploration, with clinical trials into sipuleucel-T continuing even amid a corporate restructuring and a phase III study into PROSTVAC reaching full enrollment.

The Search for Immune-Specific Biomarkers Is in Full Swing

May 04, 2015

Article

An improved understanding of how the immune system recognizes and eradicates cancer cells, along with advances in drugs that effectively promote antitumor immune responses, is revolutionizing the field of cancer therapy.

Dr. Kaufman on the Potential of T-VEC for Advanced Melanoma

March 30, 2015

Video

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Rutgers Cancer Institute of New Jersey, discusses the use of oncolytic viruses for the treatment of advanced melanoma.

Rutgers Cancer Institute of New Jersey Joins OncLive Strategic Alliance Partnership Program

February 10, 2015

Article

OncLive today welcomes Rutgers Cancer Institute of New Jersey as a partner in promoting awareness of the most recent advances in cancer care through OncLive's Strategic Alliance Partnership program

Immunotherapy Branches Out

July 18, 2014

Article

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Men With High Risk of Skeletal Complications More Likely to Develop Fractures After ADT

January 21, 2013

Article

Men with prostate cancer who had a high baseline risk of skeletal complications developed more fractures and had a higher mortality risk after long-term ADT when compared to men with lower baseline risk factors.